Ethical considerations of disclosure of iatrogenic cerebral amyloid angiopathy.

ABSTRACT: Cerebral amyloid angiopathy (CAA) causes stroke and cognitive decline. The recently identified iatrogenic CAA subtype (iCAA) is thought to be transmitted through medical procedures involving cadaveric human material and potentially neurosurgical instruments or blood transfusions. This raises ethical questions concerning disclosure of iCAA. We consider ethical arguments concerning three disclosure-related questions. Should clinicians disclose their suspicion of iCAA to patients presenting with CAA and a history of relevant exposure? Should clinicians recommend the additional tests needed for iCAA diagnosis? Should clinicians proactively identify and notify asymptomatic at-risk individuals who are unaware of their risk? We conclude that disclosure of the iCAA-diagnosis and communication of d

SUBMITTER: Kaushik K 

PROVIDER: S-EPMC12271975 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature